🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Alphatec Holdings, Inc. ATEC R2K

Healthcare · Medical Devices · United States
https://www.atecspine.com

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.

READ MORE ›
$7.75
-37.65% 1Y

Market & Price

Market Cap
$1.19B
Current Price
$7.75
High / Low (52W)
$22.68 / $6.99
Beta
0.97

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
13.42
PEG Ratio
0.48
Book Value
$-0.04
Price to Book
-221.43
P/S
1.51
EV/EBITDA
59.10
Dividend Yield
-

Profitability & Returns

ROCE
-17.04%
ROE
-
ROA
-3.81%
Profit Margin
-15.93%
Op Margin
-11.48%
EPS (Latest Qtr)
$-0.22
EPS (TTM)
$-0.83

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
1.05
Current Ratio
1.90
Debt
$603.06M
Total Assets
$791.21M
Current Assets
$450.88M
Working Capital
$231.70M

Ownership

Promoter Holding
20.35%
Chg in Prom Hold
0.00%
FII / Inst Holding
77.40%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
$1.68B
Total Revenue (TTM)
$787.08M
EBITDA
$28.40M
Free Cash Flow
$54.57M
Operating Cash Flow
$51.56M
Shares Outstanding
153.79M
Gross Margin
70.18%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
29.62%
Profit 5Y
1.75%
Revenue (YoY)
13.60%
Earnings (YoY)
-

PROS

  • Compounding revenue at 29.6% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 65.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 ATEC Alphatec Holdings, Inc. R2K 7.75 - $1.19B - -17.04% - 29.62% 1.75%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Jun 2014Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 53.17M51.01M53.63M35.58M32.33M31.69M34.79M34.21M32.24M26.71M27.09M27.98M24.38M23.10M21.31M22.04M23.00M------------------169.18M185.54M196.50M212.93M192.11M
Cost of Revenue -----------------------------------53.18M56.44M59.20M63.44M55.63M
Gross Profit 36.12M36.31M37.69M24.49M18.29M21.66M23.59M24.49M21.16M15.86M14.63M16.78M15.75M14.51M14.90M15.55M16.21M16.57M18.89M19.93M21.03M20.84M29.24M31.86M41.06M39.61M49.22M55.48M59.52M70.42M64.54M80.05M97.35M102.59M102.73M116.00M129.10M137.30M149.49M136.48M
Operating Expenses -----------------------------------147.70M140.59M146.71M154.85M158.53M
Operating Income 1.84M1.73M-1.14M-2.83M-164.68M--3.44M-320.00K-4.55M--3.40M-735.00K-1.26M-667.00K-6.54M-7.53M-10.77M-10.41M-11.60M-17.81M-11.16M-12.86M-19.05M-35.75M-35.12M-41.23M-35.75M-34.97M-40.35M-49.86M-38.36M-43.34M-35.31M-33.70M-31.71M-11.48M-9.41M-5.36M-22.06M
EBITDA ------------------------------------22.95M-8.35M4.75M11.63M-1.68M
Interest Expense -----------------------------------7.84M12.31M12.88M12.89M11.72M
Pretax Income ------------------------------------51.97M-41.18M-28.50M-21.75M-33.86M
Tax Provision ------------------------------------64.00K-37.00K74.00K-18.00K50.00K
Net Income -2.90M-3.04M-273.00K-4.56M-3.95M-160.26M-9.90M-6.62M-5.23M-13.72M-4.35M-5.51M-2.70M-3.14M-1.92M-7.08M-9.36M-12.97M-12.44M-14.57M-20.72M-15.80M-15.67M-22.90M-38.20M-43.03M-42.62M-37.10M-36.79M-43.53M-51.38M-42.65M-48.49M-40.68M-39.62M-51.91M-41.14M-28.58M-21.73M-33.91M
Diluted EPS -0.03-0.04-0.03-0.05-0.04-1.61-0.10------------------0.39-0.43-0.43-0.36-0.35-0.40-0.43-0.35-0.34-0.29-0.28-0.35-0.27-0.19-0.14-0.22
R&D Expense 4.53M---------------------------------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 120.62M171.61M197.71M196.28M204.72M154.62M134.39M120.25M101.74M----350.87M482.26M611.56M764.15M
Cost of Revenue -------------117.81M172.06M187.30M232.27M
Gross Profit 81.01M112.82M116.93M123.77M124.32M109.67M88.02M76.13M68.22M63.24M77.59M102.50M157.76M233.06M310.20M424.26M531.89M
Operating Expenses -------------354.16M458.48M547.17M589.85M
Operating Income -10.19M-11.79M-24.52M-9.84M-73.43M1.49M-175.85M-15.38M-9.00M-22.44M-47.28M-58.86M-128.06M-121.10M-148.28M-122.91M-57.97M
EBITDA --------------102.58M-110.59M-53.87M-14.92M
Interest Expense -------------5.50M16.64M24.88M45.92M
Pretax Income --------------152.01M-186.91M-162.07M-143.40M
Tax Provision --------------716.00K-277.00K50.00K-45.00K
Net Income -13.29M-14.36M-22.18M-15.46M-82.23M-12.88M-178.68M-29.93M-2.29M-28.98M-57.00M-78.99M-143.03M-151.29M-186.64M-162.12M-143.36M
Diluted EPS ----0.17-0.85-1.90-21.53-3.49-1.08-1.20--1.18-1.49-1.47-1.54-1.13-0.96
R&D Expense 13.49M16.43M16.89M14.89M14.19M16.80M17.77M----------

Compounded Sales Growth

5 Years:29.62%
1 Year:13.60%

Compounded Profit Growth

5 Years:1.75%
1 Year:-

Stock Price Performance

1 Year:-37.65%
6 Months:-64.50%
3 Months:-43.10%
1 Month:-16.67%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --377.02M366.69M382.13M365.63M344.92M146.34M94.19M84.66M129.48M169.95M261.22M-520.97M805.21M775.71M791.21M
Current Assets --------------255.63M451.09M417.40M450.88M
Cash & Equivalents 18.32M10.09M23.17M20.67M22.24M21.34M19.73M11.23M19.59M22.47M29.05M-107.77M-84.70M220.97M138.84M160.81M
Inventory --------------101.52M136.84M175.26M169.44M
Receivables --------------60.06M72.61M82.99M97.30M
Total Liabilities --------------555.63M727.09M789.88M778.78M
Current Liabilities --43.59M57.14M56.79M79.72M63.60M125.04M40.13M29.74M30.61M36.39M58.31M-138.87M157.57M153.03M219.18M
Long Term Debt --32.47M23.80M39.97M49.98M74.60M480.00K43.09M37.77M42.30M53.45M38.00M-349.51M511.04M574.52M501.41M
Total Debt --------------395.86M541.68M609.94M596.09M
Total Equity -----171.68M148.95M-36.58M-41.50M-26.66M17.57M43.63M129.88M--34.67M78.12M-14.17M12.43M
Shares Outstanding --------------108.45M141.05M145.94M150.26M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -5.55M-14.83M13.41M11.59M7.81M-20.27M10.12M-9.96M-8.73M-25.61M-33.12M-46.41M--75.13M-78.48M-44.65M45.23M
Investing Cash Flow -12.73M-14.41M-9.52M-19.40M-19.10M-11.00M-12.25M61.96M-6.50M-21.67M-13.03M-23.86M--58.28M-141.97M-93.14M-53.41M
Financing Cash Flow 10.27M43.06M-6.92M8.48M10.69M30.73M-6.53M-43.39M17.82M53.88M64.18M130.83M-31.23M356.92M56.21M30.02M
Capital Expenditure -11.76M-14.03M-8.21M-15.65M-14.35M-11.30M-12.25M-8.90M-7.60M-6.51M-13.03M-23.13M--58.28M-86.97M-93.14M-49.64M
Free Cash Flow -17.31M-28.86M5.20M-4.05M-6.54M-31.57M-2.12M-18.86M-16.32M-32.12M-46.15M-69.54M--133.41M-165.46M-137.79M-4.41M
Net Change in Cash --------------102.19M136.46M-81.58M21.84M
Share Buybacks ------------25.00M----

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 67.2%65.7%59.1%63.1%60.7%70.9%65.5%63.3%67.1%----66.4%64.3%69.4%69.6%
Operating Margin % -8.4%-6.9%-12.4%-5.0%-35.9%1.0%-130.9%-12.8%-8.8%-----34.5%-30.7%-20.1%-7.6%
Net Margin % -11.0%-8.4%-11.2%-7.9%-40.2%-8.3%-133.0%-24.9%-2.3%-----43.1%-38.7%-26.5%-18.8%
ROE % -----47.9%-8.6%488.5%72.1%8.6%-164.9%-130.6%-60.8%-436.4%-238.9%1,144.2%-1,153.8%
ROCE % --3.5%-7.9%-3.0%-25.7%0.5%-825.5%-28.4%-16.4%-22.7%-35.4%-29.0%--31.7%-22.9%-19.7%-10.1%

Shareholding Pattern

Insiders
20.35%
Institutions
77.40%
Public Float
97.18%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 6.56% 10.09M $78.18M
2 American Century Companies Inc 4.18% 6.42M $49.79M
3 Vanguard Capital Management LLC 3.20% 4.91M $38.08M
4 Royal Bank of Canada 2.94% 4.52M $35.00M
5 BNP Paribas Asset Management Holding S.A. 2.35% 3.62M $28.03M
6 State Street Corporation 1.97% 3.03M $23.49M
7 Geode Capital Management, LLC 1.89% 2.91M $22.52M
8 Nuveen, LLC 1.85% 2.85M $22.08M
9 Millennium Management Llc 1.83% 2.81M $21.77M
10 Bank of America Corporation 1.67% 2.56M $19.85M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ATEC

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks